Silexion Therapeutics Corp - Phase 2/3 Trials To Start In First Half Of 2026
Sept 4 (Reuters) - Silexion Therapeutics Corp SLXN.O:
SILEXION THERAPEUTICS ANNOUNCES SELECTION OF CONTRACT RESEARCH ORGANIZATION TO SUPPORT UPCOMING PHASE 2/3 CLINICAL TRIALS FOR SIL204
SILEXION THERAPEUTICS CORP - PHASE 2/3 TRIALS TO START IN FIRST HALF OF 2026
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Citi Raises Brent Crude Forecast to $150: Strait of Hormuz Risks Brew, How High Can Oil Prices Rise?

Amazon 2026 Q1 Earnings Preview: AWS and Advertising Dual Engines Power Ahead, Can They Allay Market Doubts?

Google Bets $40B on Anthropic: Is Google Cloud the New Growth Engine as Meta Challenges Ad Dominance?

Is Meta Platforms Stock a Smart Buy Ahead of Q1 2026 Earnings? Unpacking AI Growth and Investment Potential

Fed FOMC Preview: No Rate Cuts Become Consensus, Warsh Succession Imminent

Tradingkey







